AbCellera Biologics Inc
For the period ended Jun 30, 2024. Filed Aug 6, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 6, 2024
ABCL$12.46-0.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(Expressed in thousands of U.S. dollars.)
| Six months ended June 30, | ||
|---|---|---|
| 2023 | 2024 | |
| Cash flows from operating activities: | ||
| Net loss | $(70,638) | $(77,540) |
| Cash flows from operating activities: | ||
| Depreciation of property and equipment | 5,810 | 6,603 |
| Amortization and impairment of intangible assets | 5,314 | 34,763 |
| Amortization of operating lease right-of-use assets | 3,252 | 3,437 |
| Stock-based compensation | 31,873 | 35,191 |
| Fair value gain on contingent consideration | – | (30,920) |
| Other | (4,429) | (8,193) |
| Changes in operating assets and liabilities: | ||
| Research fees and grants receivable | (24,269) | (34,434) |
| Accrued royalties receivable | 9,260 | – |
| Income taxes payable (receivable) | 22,884 | (5,953) |
| Accounts payable and accrued liabilities | (2,827) | (130) |
| Deferred revenue | (4,870) | (12,782) |
| Accrued royalties payable | (16,253) | – |
| Deferred grant income | 25,566 | 19,757 |
| Other assets | (4,833) | (1,473) |
| Net cash used in operating activities | (24,160) | (71,674) |
| Cash flows from investing activities: | ||
| Purchases of property and equipment | (42,185) | (44,250) |
| Purchase of marketable securities | (528,891) | (426,007) |
| Proceeds from marketable securities | 422,814 | 539,385 |
| Receipt of grant funding | 7,693 | 19,750 |
| Long-term investments and other assets | (36,757) | 3,950 |
| Investment in equity accounted investees | (6,673) | (10,820) |
| Net cash provided by (used in) investing activities | (183,999) | 82,008 |
| Cash flows from financing activities: | ||
| Payment of liability for in-licensing agreement and other | (863) | (368) |
| Proceeds from long-term liabilities | – | 4,497 |
| Proceeds from exercise of stock options | 824 | 1,353 |
| Net cash provided by (used in) financing activities | (39) | 5,482 |
| Effect of exchange rate changes on cash and cash equivalents | 584 | (824) |
| Increase (decrease) in cash and cash equivalents | (207,614) | 14,992 |
| Cash and cash equivalents and restricted cash, beginning of period | 414,651 | 160,610 |
| Cash and cash equivalents and restricted cash, end of period | $207,037 | $175,602 |
| Restricted cash included in other assets | 2,290 | 2,290 |
| Total cash, cash equivalents, and restricted cash shown on the balance sheet | $204,747 | $173,312 |
| Supplemental disclosure of non-cash investing and financing activities | ||
| Property and equipment in accounts payable | 11,718 | 15,944 |
| Right-of-use assets obtained in exchange for operating lease obligation | 2,945 | 452 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.